viral tropism

43
Viral tropism VIRAL TROPISM UK CAB 22 13 July 2007 Matt Williams

Upload: jessie

Post on 16-Jan-2016

62 views

Category:

Documents


0 download

DESCRIPTION

VIRAL TROPISM UK CAB 22 13 July 2007 Matt Williams. Viral tropism. Tropic = shape response. [from Middle English tropik, Old French tropique, Latin tropicus, Greek tropikos, turn] Viral tropism = the way the virus responds to external stimulus in order to attach to and infect cells. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Viral tropism

Viral tropism

VIRAL TROPISM

UK CAB 22 13 July 2007

Matt Williams

Page 2: Viral tropism

Viral tropism

Tropic = shape response. [from Middle English tropik, Old French tropique, Latin tropicus, Greek tropikos, turn]

Viral tropism = the way the virus responds to external stimulus in order to attach to and infect cells

Page 3: Viral tropism

Viral tropism

Page 4: Viral tropism

Viral tropism

Page 5: Viral tropism

Viral tropism

Scientists studying HIV-1 discovered by the 1990s that different forms of HIV use different coreceptors to attach to cells.

Page 6: Viral tropism

Viral tropism

The most commonly-transmitted strains of HIV use the CCR5 coreceptor - strains that develop in (contribute to?) late-stage infection often use CXCR4

Page 7: Viral tropism

Viral tropism

R5 = HIV strains which use the CCR5 coreceptor

X4 = HIV strains which use the CXCR4 coreceptor

Page 8: Viral tropism

Viral tropism

During the early stages of infection HIV mainly targets macrophages using the CCR5 coreceptor (called M-tropic)

Page 9: Viral tropism

Viral tropism

During later stages of infection HIV isolates are T-cell tropic and use the CXCR4 coreceptor (T-tropic)

Page 10: Viral tropism

Viral tropism

There are also R5X4 strains of HIV which can use either of these receptors.

Page 11: Viral tropism

Viral tropism

Balance of an HIV infection can be mixed between X4 and R5 and change over time

Page 12: Viral tropism

Viral tropism

Viral tropism is important for a new class of drugs called CCR5 agonists. These are a kind of entry inhibitor (like T-20) and stop HIV binding to cells by blocking the CCR5 coreceptor.

Page 13: Viral tropism

Viral tropism

Viral tropism can be tested for.

The tropism test that you need to take before using a CCR5 inhibitor only works if your viral load is over 500 copies/mL.

1 routine test – more in development

Page 14: Viral tropism

Viral tropism

Page 15: Viral tropism

Viral tropism

Page 16: Viral tropism

Viral tropism

Page 17: Viral tropism

Viral tropism

Page 18: Viral tropism

Viral tropism

HIV carries on its surface "spikes" which are the glycoprotein known as gp120.

Page 19: Viral tropism

Viral tropism

HIV virus connects with a CD4+ marker sticking out of a cell and a coreceptor - like two pieces of jigsaw joining together

Once HIV attaches to a cell in this way it can merge with the cell.

Page 20: Viral tropism

Viral tropism

There are other types of cell which carry CD4 on their surface besides T-cells eg macrophages

Page 21: Viral tropism

Viral tropism

CD4 is part of the immunolgobulin superfamily

immnoglobulin = general term for antibodies which bind onto invading organisms

Page 22: Viral tropism

Viral tropism

Page 23: Viral tropism

Viral tropism

HIV will not successfully complete the binding/fusion stages unless a coreceptor is present on the cell surface in addition to the CD4 immunoglobulin marker.

Page 24: Viral tropism

Viral tropism

...coreceptor...

T-cells – X4 or R5

Macrophages - R5

Page 25: Viral tropism

Viral tropism

X4 and R5 are chemokines - chemical messengers that signal to white blood cells to mobilise and activate

Page 26: Viral tropism

Viral tropism

Syncytia formation

Syncytia = large groups of cells

Page 27: Viral tropism

Viral tropism

Syncytia formation

When an infected cell starts producing HIV proteins, the HIV env proteins migrate to the cell membrane and (maybe) poke out of the cell - this means that the infected cell can now bind to other cells with the CD4 protein on their surface...

Page 28: Viral tropism

Viral tropism

Syncytia formation

...so an infected CD4+ cell can join with a healthy CD4+ cell and merge. The membranes fuse and become one. This repeats, and eventually you have one large HIV-infected CD4+ cell with many nuclei - as many as 500.

Page 29: Viral tropism

Viral tropism

Page 30: Viral tropism

Viral tropism

Syncytia = clinical undesirable (inevitable?) = advanced disease

Autopsies have often found syncytia in the brains of HIV-positive people who had serious neurological complications

Page 31: Viral tropism

Viral tropism

Syncytia formation seems to relate to X4-using HIV

X4 and R5-using HIV seems to be in competition

Page 32: Viral tropism

Viral tropism

Studies

Harrigan - retrospective evaluation of samples and records from 806 participants in a cohort of treatment naive-adults in British Columbia

Moyle – evaluation of data and coreceptor phenotype in a collection of 169 stored samples from treatment-naive individuals

Page 33: Viral tropism

Viral tropism

Studies

Harrigan

Detection of R5/X4 or X4 phenotype increased from 6% in people with CD4 counts above 500 cells/mm3 to over 50% in those with CD4 counts below 25 cells/mm3. One exclusively X4 phenotype sample in the cohort.

Page 34: Viral tropism

Viral tropism

Studies

Harrigan

Odds of having X4-using virus increased by about 1.5-fold in people with CD4 counts between 200 and 500 compared to those above 500

Page 35: Viral tropism

Viral tropism

Studies

Harrigan PR, et al. Prevalence, predictors and clinical impact of baseline HIV co-receptor usage in a large cohort of antiretroviral naive individuals starting HAART.

Abstract MoPeB3117. 2004 IAC, Bangkok

Page 36: Viral tropism

Viral tropism

Studies

Moyle

Detection of the R5/X4 phenotype ranged from about 7% in samples with CD4 counts above 300 to 46% in those with CD4 counts below 100. No exclusively X4 phenotype. Mean CD4 count for R5 samples was 307 versus 117 for R5/X4.

Page 37: Viral tropism

Viral tropism

Studies

Moyle GJ, et al. Prevalence and predictive factors for CCR5 and CXCR4 co-receptor usage in a large cohort of HIV-1 positive individuals.

Abstract WePeB5725. 2004 IAC, Bangkok

Page 38: Viral tropism

Viral tropism

Studies

In neither study was viral load a significant predictor of co-receptor usage phenotype

Harrigan - injection drug use was not correlated with having R5 or X4 HIV

Moyle - no difference between B and non-B HIV subtypes

Page 39: Viral tropism

Viral tropism

CCR5 resistance

env gene and V3 (not routine test yet)

Page 40: Viral tropism

Viral tropism

CCR5 and resistance - articles

Mutations Outside V3 Loop May Further Resistance to CCR5 Drugs http://www.natap.org/2007/ResisWksp/ResisWksp_15.htm

Treatment failure and tropism changes in maraviroc trial related to previously undetected CXCR4, rather than a mutational shift from CCR5http://www.i-base.info/htb/v8/htb8-6-7/Treatment.html

Mechanisms of failure to CCR5 inhibitors is not explained by mutation in the V3 loop, cross-resistance between CCR5 inhibitors is likelyhttp://www.i-base.info/htb/v8/htb8-6-7/Mechanisms.html

Page 41: Viral tropism

Viral tropism

Viral tropism and treatment - articles

HIV resistance mutations common but CXCR4 rare among untreated US gay men http://www.aidsmap.com/en/news/821F9F52-A44A-4D7F-B6D8-9A281D4B4CCC.asp

CXCR4, dual or mixed tropic HIV does not reduce response to HAARThttp://www.aidsmap.com/en/news/5FFD235B-6D39-42A7-88D6-731BE5B7E24F.asp

HIV may use different coreceptors in blood and brainhttp://www.i-base.info/htb/v7/htb7-10/hiv.html

Page 42: Viral tropism

Viral tropism

Viral tropism and treatment – articles

Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunological effect http://www.i-base.info/htb/v7/htb7-9/Maraviroc.html

Patients treated with maraviroc with X4-tropic virus had increases in CD4 cell count consistent with the overall maraviroc-treated population at treatment failure

Mayer H, van der Ryst E, Saag M et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimised background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. IAS Toronto, 2006. Abstract late breaker THLB0215

Page 43: Viral tropism

Viral tropism

Molecules of HIVDan Stowell

http://www.mcld.co.uk/hiv